tiprankstipranks
Dr. Reddy’s Sells Non-Strategic Louisiana Subsidiary
Company Announcements

Dr. Reddy’s Sells Non-Strategic Louisiana Subsidiary

Story Highlights

Stay Ahead of the Market:

An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.

Dr. Reddy’s Laboratories has announced the sale of its wholly owned subsidiary, Dr. Reddy’s Laboratories Louisiana LLC, along with its manufacturing facility in Shreveport, Louisiana, USA, to Jaguar Labs Holdings, LLC. This facility is deemed non-strategic, contributing a minimal percentage to the company’s consolidated income and net worth. The transaction is not considered a related party transaction and is expected to be completed by March 18, 2025.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in India, primarily engaged in the production and distribution of generic medicines and active pharmaceutical ingredients. It focuses on providing affordable and innovative medicines to a wide range of markets globally.

YTD Price Performance: 0.0%

Average Trading Volume: 1,207,457

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $13.13B

For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskDr. Reddy’s to Announce Q3FY25 Financial Results on January 23, 2025
TipRanks Auto-Generated NewsdeskDr. Reddy’s Laboratories’ Credit Rating Reaffirmed by ICRA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App